DOI  10.17613/hgd2-y320 

 Download  PDF         Open  PDF 

Review Article

Study on Osteoporosis Treatment in Older Adults

Campa-Ferrusca, Adán T.1; Deanda-Quintero, Javier2; Rodríguez-Avalos, Marcos T.1; Silva-Ruiz, Rosendo3; Sánchez-Martínez, Joana K.4; Medina-Martinez, I. Alejandro5.

Correspondence: irvingalejandromm4@gmail.com

¹Department of Internal Medicine, ISSSTE General Hospital, SLP, México.
²Department of Internal Medicine, Querétaro General Hospital, México.
³Department of Teaching and Internal Medicine, ISSSTE General Hospital, SLP, México.
⁴Department of Gynecology and Obstetrics, ISSSTE General Hospital, Querétaro, México.
⁵Department of General Surgery, ISSSTE General Hospital, Querétaro, México.

KEYWORDS: Osteoporosis, older adults, treatment.

ABSTRACT: The treatment of osteoporosis is becoming more and more relevant because of the accelerated aging of the world's population, which is why its study and development is of great importance for health personnel and the scientific community.

OBJECTIVE: To study the treatment for osteoporosis in older adults.

MATERIAL AND METHODS: We carried out a systematic review using the PRISMA system, using the Pub Med search engine and the combination of words (treatment) AND (osteoporosis) AND (older) AND (adults) obtaining 4,365 results, which were reduced to 1,218 after filtering those that were published from 2019-2024 and, after excluding writings taken from books or documents, 330 articles were obtained.  From this grand total we selected 45 articles, of which 30 were included in this review.

RESULTS: The indication for pharmacological treatment is not related to sex, the use of Alendronate, Risedronate, Zoledronic Acid, Ibandronate, Denosumab, Teriparatide and Romozumab is the same in men and women.

CONCLUSIONS: The treatment of osteoporosis has many options; it must be personalized, according to the clinical characteristics of each patient, as well as its follow-up.

CONFLICTS OF INTERESTS

The authors have no conflict of interest

BIBLIOGRAPHY

1.    Johnston CB, Dagar M. Osteoporosis in Older Adults. Medical Clinics of North America [Internet]. 2020 Sep;104(5):873–84. Disponible en: https://doi.org/10.1016/j.mcna.2020.06.004

2.    Salari N, Darvishi N, Bartina Y, Larti M, Kiaei A, Hemmati M, et al. Global prevalence of osteoporosis among the world older adults: a comprehensive systematic review and meta-analysis. J Orthop Surg Res [Internet]. 2021;16(1). Disponible en: https://doi.org/10.1186/s13018-021-02821-8

3.    Meng F, Dong M, Guo J, Xu S, Yan W, Gu J, et al. Osteoporosis in community-dwelling older adults: Prevalence and prevention and control strategies in general practice. Chinese General Practice Journal [Internet]. 2024;1(1):35–41. Disponible en : https://doi.org/10.1016/j.cgpj.2024.03.009

4.    Ballesteros J, Rivas D, Duque G. The role of the kynurenine pathway in the pathophysiology of frailty, sarcopenia, and osteoporosis. Nutrients [Internet]. 2023;15(14):3132. Disponible en: http://dx.doi.org/10.3390/nu15143132

5.    Aibar-Almazán A, Voltes-Martínez A, Castellote-Caballero Y, Afanador-Restrepo DF, Carcelén-Fraile M del C, López-Ruiz E. Current status of the diagnosis and management of osteoporosis. Int J Mol Sci [Internet]. 2022;23(16):9465. Disponible en: https://doi.org/10.3390/ijms23169465

6.    Zhang J, Hu Y, Cai W. Bone metabolism factors in predicting the risk of osteoporosis fracture in the elderly. BMC Musculoskelet Disord [Internet]. 2024 ; 25 : 442. Disponible en: https://doi.org/10.1186/s12891-024-07560-5

7.    Kemmler W, Kohl M, Fröhlich M, Jakob F, Engelke K, von Stengel S, et al. Effects of high-intensity resistance training on osteopenia and sarcopenia parameters in older men with osteosarcopenia—one-year results of the randomized controlled Franconian Osteopenia and Sarcopenia Trial (FrOST). J Bone Miner Res [Internet]. 2020;35(9):1634-1644.  Disponible en : https://doi.org/10.1002/jbmr.4027

8.    Feehan J, Al Saedi A, Duque G. Targeting fundamental aging mechanisms to treat osteoporosis. Expert Opin Ther Targets [Internet]. 2019;23(12):1031–9. Disponible en: https://doi.org/10.1080/14728222.2019.1702973

9.    Wu D, Li L, Wen Z, Wang G. Romosozumab in osteoporosis: yesterday, today and tomorrow. J Transl Med [Internet]. 2023;21(1).  Disponible en : https://doi.org/10.1186/s12967-023-04563-z

10. Barnsley J, Buckland G, Chan PE, Ong A, Ramos AS, Baxter M, et al. Pathophysiology and treatment of osteoporosis: challenges for clinical practice in older people. Aging Clin Exp Res [Internet]. 2021;33(4):759–73. Disponible en: http://dx.doi.org/10.1007/s40520-021-01817-y

11. Patel D, Gorrell C, Norris J, Liu J. A narrative review of the pharmaceutical management of osteoporosis. Ann Jt [Internet]. 2023;8:25–25. Disponible en: https://dx.doi.org/10.21037/aoj-23-2

12. Sugimoto T, Shiraki M, Fukunaga M, Kishimoto H, Hagino H, Sone T, et al. Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study. Osteoporos Int [Internet]. 2019;30(11):2321-31. Disponible en: https://doi.org/10.1007/s00198-019-05111-6

13. Nakamura T, Fukunaga M, Nakano T, Kishimoto H, Ito M, Hagino H, et al. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study). Osteoporosis Int [Internet]. 2017;28(1):389–98. Disponible en: https://doi.org/10.1007/s00198-016-3736-y

14. Shiraki M, Kuroda T, Takeuchi Y, Sugimoto T, Tanaka S, Suzuki H, et al. Acute phase reactions after intravenous infusion of zoledronic acid in Japanese patients with osteoporosis: Sub-analyses of the phase III ZONE study. Calcif Tissue Int [Internet]. 2021;109(6):666–74. Disponible en: https://doi.org/10.1007/s00223-021-00884-7

15. Okimoto N, Sakai A, Yoshioka T, Kobayashi T, Asano K, Akahoshi S, et al. Efficacy of non-steroidal anti-inflammatory drugs on zoledronic acid-induced acute-phase reactions: randomized, open-label, Japanese OZ study. J Bone Miner Metab [Internet]. 2020;38(2):230–9.  Disponible en: https://doi.org/10.1007/s00774-019-01050-8

16. Sølling AS, Harsløf T, Langdahl B. Treatment with zoledronate subsequent to denosumab in osteoporosis: A 2-year randomized study. J Bone Miner Res [Internet]. 2021;36(7):1245-1254. Disponible en: https://doi.org/10.1002/jbmr.4305

17. Cedeno-Veloz BA, Erviti López J, Gutiérrez-Valencia M, Leache Alegría L, Saiz LC, Rodríguez García AM, et al. Efficacy of antiresorptive treatment in osteoporotic older adults: A systematic review and meta-analysis of randomized clinical trials. J Nutr Health Aging [Internet]. 2022;26(8):778–85. Disponible en : https://doi.org/10.1007/s12603-022-1825-5

18. Reid IR, Bolland MJ. Calcium and/or vitamin D supplementation for the prevention of fragility fractures: Who needs it? Nutrients [Internet]. 2020;12(4):1011. Disponible en: https://doi.org/10.3390/nu12041011

19. Chevalley T, Brandi ML, Cashman KD, Cavalier E, Harvey NC, Maggi S, et al. Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group. Aging Clin Exp Res [Internet]. 2022;34(11):2603–23.  Disponible en : https://doi.org/10.1007/s40520-022-02279-6

20. Reid IR. Osteoporosis: evidence for vitamin D and calcium in older people. Drug Ther Bull [Internet]. 2020;58(8):122–5. Disponible en: https://doi.org/10.1136/dtb.2019.000063

21. Jiang Y, Tang H, Ma X, Cheng Q, Lin H, Jin X, et al. Eldecalcitol increases bone mineral density in Chinese osteoporotic patients without vitamin D or calcium supplementation. J Bone Miner Metab [Internet]. 2019;37(6):1036–47. Disponible en: https://doi.org/10.1007/s00774-019-01009-9

22. Mochizuki T, Yano K, Ikari K, Okazaki K. Two-year effectiveness of zoledronic acid with or without eldecalcitol in Japanese patients with osteoporosis: A randomized prospective study. Osteoporos Sarcopenia [Internet]. 2022;8(2):75–9. Disponible en: https://doi.org/10.1016/j.afos.2022.05.001

23. Zanker J, Duque G. Osteoporosis in older persons: Old and new players. J Am Geriatr Soc [Internet]. 2019;67(4):831–40. Disponible en: http://dx.doi.org/10.1111/jgs.15716

24. Zhou J, Liu B, Qin M, Liu J. Fall Prevention and Anti‐Osteoporosis in Osteopenia Patients of 80 Years of Age and Older: A Randomized Controlled Study. Orthopaedic Surgery [Internet].  2020 Jun;12(3):890–9. Disponible en: https://doi.org/10.1111/os.12701

25. Van Camp L, Dejaeger M, Tournoy J, Gielen E, Laurent MR. Association of orthogeriatric care models with evaluation and treatment of osteoporosis: a systematic review and meta-analysis. Osteoporos Int [Internet]. 2020;31(11):2083–2092. Disponible en: https://doi.org/10.1007/s00198-020-05512-y

26. Leslie WD, Morin SN, Martineau P, Bryanton M, Lix LM. Association of bone density monitoring in routine clinical practice with anti-osteoporosis medication use and incident fractures: A matched cohort study. J Bone Miner Res [Internet]. 2019;34(10):1808-1814. Disponible en: https://doi.org/10.1002/jbmr.3813

27. Beaudart C, Demonceau C, Sabico S, Veronese N, Cooper C, Harvey N, et al. Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis. Aging Clin Exp Res [Internet]. 2023;35(9):1789–806. Disponible en: https://doi.org/10.1007/s40520-023-02478-9

28. Gai QY, Lv H, Li YP, Fu QM, Li P. Education intervention for older adults with osteoporosis: a systematic review. Osteoporos Int [Internet]. 2020;31(4):625–35. Disponible en: http://dx.doi.org/10.1007/s00198-019-05166-5

29. Leslie WD, Crandall CJ. Population-based osteoporosis primary prevention and screening for quality of care in osteoporosis, current osteoporosis reports. Curr Osteoporos Rep [Internet]. 2019;17(6):483–90. Disponible en: https://doi.org/10.1007/s11914-019-00542-w

30. Zhao D-C, Lin X-Y, Hu J, Zhou B-N, Zhang Q, Wang O, et al. Health-related quality of life of men with primary osteoporosis and its changes after bisphosphonates treatment. BMC Musculoskelet Disord [Internet]. 2023;24(1). Disponible en: https://doi.org/10.1186/s12891-023-06397-8